The US biotech group Moderna has to cut sales targets for its Covid 19 vaccine this year due to supply bottlenecks. For 2022, sales of Covid-19 vaccines are now expected to be between $18 billion and $19 billion instead of $21 billion, the company announced on Thursday. Details of the delivery problems were not given. Moderna’s coronavirus vaccine sales fell 35 percent to $3.1 billion in the third quarter. The group’s net profit shrank to a good billion dollars from 3.3 billion a year ago. Just a few days ago, competitor Pfizer raised the forecast for its corona vaccine developed with the German biotech company BioNTech and now expects $34 billion, two billion more than before – thanks to the additional business with the adapted omicron boosters. However, the demand for the original corona vaccines has decreased worldwide.
Vaccines – Moderna Supply Bottlenecks – Economy
